Eli Lilly (LLY)CEO bought ~$1.05M

~$1.05M

Approx. value · 1,632 sh @ $644.77

547K

Holds after · shares reported

Traded

Aug 12, 2025

Filed

Aug 12, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Oct 29, 2024CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
2. Dec 11, 2024Congress · 2 peopleMembers of Congress: 2 purchases
3. Apr 23, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
4. May 6, 2025CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
5. May 12, 2025CongressDisclosed sale of LLY — reported range $100,001 - $250,000
6. May 21, 2025CongressDisclosed sale of LLY — reported range $1,001 - $15,000
7. Jun 3, 2025CongressDisclosed sale of LLY — reported range $15,001 - $50,000
8. Jun 9, 2025CongressDisclosed partial sale of LLY — reported range $1,001 - $15,000
9. Jul 1, 2025FDAFDA drug approval: Kisunla
10. Jul 10, 2025Congress · 1 personMembers of Congress: 2 purchases
11. Jul 16, 2025Congress · 1 personMembers of Congress: 2 sales
12. Jul 24, 2025Insider · 1 personInsiders: 6 sales (~$225.4M)
13. Aug 8, 2025InsiderDirector purchased ~$128K of LLY shares in the open market
14. Aug 11, 2025InsiderOfficer sold ~$784K of LLY shares in the open market
15. Aug 11, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
16. Aug 12, 2025 · this disclosureInsiderCEO purchased ~$1.05M of LLY shares in the open market

What came next

1. Aug 12, 2025Insider · 3 peopleInsiders: 4 purchases (~$1.7M)
2. Aug 13, 2025Insider · 2 peopleInsiders: 2 purchases (~$1.1M)
3. Aug 14, 2025Congress · 2 peopleMembers of Congress: 2 purchases, 1 sale
4. Aug 15, 2025InsiderCFO purchased ~$495K of LLY shares in the open market
5. Aug 22, 2025CongressDisclosed purchase of LLY — reported range $1,001 - $15,000
6. Aug 28, 2025InsiderOfficer sold ~$735K of LLY shares in the open market
7. Sep 18, 2025Insider · 1 personInsiders: 5 sales (~$81.5M)
8. Sep 19, 2025Insider · 1 personInsiders: 2 sales (~$18.1M)
9. Sep 25, 2025FDAFDA drug approval: Inluriyo
10. Oct 1, 2025Insider · 1 personInsiders: 38 sales (~$210.3M)
11. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
12. Oct 30, 20255% stakeThe Vanguard Group reported a passive stake (13G) of 8.6%
13. Oct 30, 20255% stakeLILLY ENDOWMENT, INC. reported a passive stake (13G) of 10.1%
14. Nov 18, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 18, 2025, the Board of Directors (the “Board”) of Eli Lilly and Company (the “Company”) elected Carolyn R. Bertozzi, Ph.D as a new member of the Board, effective December 8, 2025.”
15. Nov 20, 2025FDAFDA drug approval: Retevmo
16. Nov 20, 2025FDAFDA drug approval: Retevmo

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Eli Lilly

For Eli Lilly, OQRO holds 7 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports, 189 fund holdings reports (13F) and 1 federal contract award dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LLY page.

Other recent filings by David A Ricks, President, Chair, and CEO

• SEC Form 4 at Adobe (ADBE)Jun 26, 2026
• SEC Form 4 at Adobe (ADBE)Jan 31, 2025

The full history of David A Ricks, President, Chair, and CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Eli Lilly

• SEC Form 144Oct 7, 2026
• USAspending.gov award recordSep 1, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 25, 2026
• SEC Form 4Aug 18, 2026
• SEC Form 13F-HRAug 18, 2026

Everything OQRO holds on this company is on its LLY page.